A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.

被引：0
|
作者：
Javle, Milind M.
Sadeghi, Saeed
El-Khoueiry, Anthony B.
Goyal, Lipika
Philip, Philip Agop
Kelley, Robin Kate
Borbath, Ivan
Macarulla, Teresa
Yong, Wei-Peng
Tanasanvimon, Suebpong
Pande, Amit
Li, Gary
Howland, Michael
Berman, Craig
Abou-Alfa, Ghassan K.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif Los Angeles, Santa Monica, CA USA
[3] USC Kenneth Norris Comprehens Canc Ctr, Los Angeles, CA USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Clin Univ St Luc, Brussels, Belgium
[8] Hosp Valle De Hebron, Barcelona, Spain
[9] Natl Univ Canc Inst, Singapore, Singapore
[10] Chulalongkorn Univ, Bangkok, Thailand
[11] QED Therapeut Inc, San Francisco, CA USA
[12] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4591
引用
收藏
页数：2
相关论文
共 50 条
  • [21] D Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: A retrospective analysis
    Gupta, K.
    Parthiban, S.
    Kumar, S.
    Srinivas, S.
    Vallathol, D. H.
    Chanana, R.
    Grewal, G. S.
    Rathnasamy, N.
    Goel, A.
    Bajpai, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 128 - 128
  • [22] First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
    Moehring, Christian
    Feder, Jan
    Mohr, Raphael U.
    Sadeghlar, Farsaneh
    Bartels, Alexandra
    Mahn, Robert
    Zhou, Taotao
    Marinova, Milka
    Feldmann, Georg
    Brossart, Peter
    von Websky, Martin
    Matthaei, Hanno
    Manekeller, Steffen
    Glowka, Tim
    Kalff, Joerg C.
    Weismueller, Tobias J.
    Strassburg, Christian P.
    Gonzalez-Carmona, Maria A.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
    Goff, Laura Williams
    Lowery, Maeve Aine
    Jordan, Emmet
    Wang, Rui
    Bocobo, Andrea Grace
    Chou, Joanne F.
    O'Reilly, Eileen Mary
    Harding, James J.
    Kemeny, Nancy E.
    Capanu, Marinela
    Griffin, Ann C.
    McGuire, Joseph P.
    Venook, Alan P.
    Abou-Alfa, Ghassan K.
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
    Lowery, Maeve Aine
    Goff, Laura Williams
    Jordan, Emmet
    Wang, Rui
    Bocobo, Andrea Grace
    Chou, Joanne F.
    O'Reilly, Eileen Mary
    Harding, James J.
    Kemeny, Nancy E.
    Capanu, Marinela
    Griffin, Ann
    McGuire, Joseph P.
    Venook, Alan P.
    Abou-Alfa, Ghassan K.
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [25] MATCHING-ADJUSTED INDIRECT COMPARISON OF FUTIBATINIB VERSUS CHEMOTHERAPY AND PEMIGATINIB IN CHOLANGIOCARCINOMA PATIENTS WITH FGFR2 FUSIONS/REARRANGEMENTS
    Paine, A.
    Thom, H.
    Wacheck, V
    He, Y.
    Kazerooni, R.
    Salimi, T.
    Borad, M. J.
    Bridgewater, J.
    VALUE IN HEALTH, 2022, 25 (12) : S33 - S33
  • [26] Global Expanded Access Program (EAP) to pemigatinib for patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements
    Lindley, Anouk
    Prager, Gerald
    Bitzer, Michael
    Burn, Timothy C.
    Lihou, Christine F.
    Richards, Elisabeth Croft
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 82 - 82
  • [27] Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies
    Salah, Samer
    Lee, Jae-Lyun
    Rozzi, Antonio
    Kitamura, Hiroshi
    Matsumoto, Kazumasa
    Vis, Daniel J.
    Srinivas, Sandy
    Morales-Barrera, Rafael
    Carles, Joan
    Al-Rimawi, Dalia
    Lee, Soonil
    Kim, Ki Hong
    Izumi, Kouji
    Lewin, Jeremy
    CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : E563 - E571
  • [28] Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
    Schram, A.
    Borad, M.
    Sahai, V.
    Kamath, S.
    Kim, R.
    Liao, C. Y. A.
    Oh, D. Y.
    Ponz-Sarvise, M.
    Yachnin, J.
    Shell, S. A.
    Cassier, P.
    Dotan, E.
    Florou, V.
    Moreno, V.
    Park, J. O.
    Tai, D.
    Schmidt-Kittler, O.
    Ferte, C.
    Goyal, L.
    Subbiah, V.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S116 - S116
  • [29] The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis
    Dakik, Hassan K.
    Moskovic, Daniel J.
    Carlson, Peter J.
    Tamm, Eric P.
    Qiao, Wei
    Wolff, Robert A.
    Abbruzzese, James L.
    Fogelman, David R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 425 - 430
  • [30] The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis
    Hassan K. Dakik
    Daniel J. Moskovic
    Peter J. Carlson
    Eric P. Tamm
    Wei Qiao
    Robert A. Wolff
    James L. Abbruzzese
    David R. Fogelman
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 425 - 430
12345